A new radiotherapy approach provides high precision with excellent dose stability throughout complex rotational treatments. Static delivery provided by the dose control option also benefits from a more stable and consistent dose rate at every gantry angle.

Accuray, Inc. (Sunnyvale, CA, USA), a radiation oncology company, announced that the US Food and Drug Administration (FDA) has granted the company 510(k) clearance to market the dose control system (DCS), a new feature for Accuray’s TomoTherapy system that improves system performance.

The TomoTherapy system transformed radiation therapy with the introduction of helical delivery, providing precise application of dose to target structures while sparing healthy tissue. With the advent of the dose control system, the TomoTherapy system is the first dose servo-controlled helical delivery system.

The new DCS feature provides these gains by automatically adjusting controls earlier handled through a manual process. This means small variations in dose rate are immediately corrected by the system, resulting in fewer interruptions. The DCS application also provides a more stable output over longer duration treatments, such as total marrow and total body irradiation. The result of this new feature is a better patient experience and improved overall system performance.

“FDA clearance of the new dose control system is a positive step toward improving TomoTherapy system performance and customer satisfaction,” said Euan S. Thomson, PhD, president and chief executive officer of Accuray. “We are dedicated to offering our customers technological advancements that help streamline their workflow and expand the capabilities of their systems.”

 

Guangzhou Jia Yu medical equipment Limited